CADTH pan-Canadian Oncology Drug Review (pCODR)
Call for feedback deadline: March 28, 2019, at 5:00 p.m. EDT
In December 2018, CADTH and the Canadian Association of Provincial Cancer Agencies (CAPCA) announced that we would be exploring how some of the implementation functions of the Cancer Drug Implementation Advisory Committee (CDIAC) could be transferred to CADTH. The primary function of CDIAC is to provide advice (generally prior to the initiation of the pan-Canadian Pharmaceutical Alliance negotiations) about how new drugs can be integrated into a therapeutic area with currently funded drugs and how this impacts existing drugs within the treatment space to achieve greater consistency in drug funding decisions across Canada.
The objective of transitioning the functions of CDIAC is to support the harmonization of cancer drug funding decisions across Canada; this is part of our commitment to introducing greater transparency and stakeholder engagement to the cancer drug review process. In view of this, CADTH, with the endorsement of the CAPCA Board of Directors in principle, is proposing a model to integrate key functions of CDIAC into CADTH’s pan-Canadian Oncology Drug Review (pCODR) program to support continuous process improvements that enhance efficiency and timeliness, and reduce duplication of effort. To facilitate a successful model to integrate the CDIAC functions, there will be a number of factors and steps that will need to be considered by all stakeholders.
CADTH, in collaboration with CAPCA, invites stakeholder input on the proposed changes to the pCODR process. The following is a link to the consultation document that sets out the background information and proposal concept.
As part of this consultation, CADTH and CAPCA will be holding a webinar on Monday, March 4, 2019, from 12:00 p.m. to 1:00 p.m. EST. Panelists Heather Logan (Senior Advisor, CADTH), Alexandra Chambers (Director, pCODR), and Erika Brown (Interim Executive Director, CAPCA) will outline key concepts of the proposal. The webinar is open to everyone and will provide an opportunity for participants to engage in a dialogue about this proposal. Advance registration is required, and registration will close on Friday, March 1, 2019, at 5:00 p.m. EST.
How to Submit Your Feedback
To provide your comments on the proposal, please use the Survey Monkey feedback template.
Feedback must be received by CADTH by 5:00 p.m. EDT on March 28, 2019. For feedback to be considered, you must identify yourself to CADTH. Only one response per organization will be considered. If more than one response is received, only the first will be considered.
Following the consultation period, CADTH will carefully assess all stakeholder feedback before announcing any decisions regarding changes to the current pCODR process. The submissions may be used by CADTH for consideration in making changes to the pCODR process. This may involve disclosing some or all comments or materials, or summaries of them, to CADTH’s advisory bodies and participating jurisdictions, as well as to CAPCA during and after the consultation. If for any reason you feel your submission should not be shared with other parties, please indicate this in your submission. Any future changes will be applied to the pCODR procedures and guidelines, and will be announced as part of our CADTH Pharmaceutical Reviews Update. We thank you in advance for your interest.
If you have any questions about the feedback process, please email us at email@example.com.